Marker Therapeutics (MRKR) Total Current Liabilities (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Total Current Liabilities data on file, last reported at $3.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $3.6 million, up 45.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (up 45.44% YoY), and the FY2025 annual result was $2.3 million, down 34.36% from the prior year.
• Total Current Liabilities climbed to $3.6 million in Q1 2026 per MRKR's latest filing, from $2.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.5 million in Q2 2022 and troughed at $2.0 million in Q2 2024.
• A 5-year average of $4.8 million and a median of $3.5 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 138.07% in 2022, then sank 78.32% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $7.8 million in 2022, then tumbled by 60.49% to $3.1 million in 2023, then grew by 12.67% to $3.5 million in 2024, then plunged by 34.36% to $2.3 million in 2025, then jumped by 59.97% to $3.6 million in 2026.
• Business Quant data shows MRKR's Total Current Liabilities at $3.6 million in Q1 2026, $2.3 million in Q4 2025, and $3.3 million in Q3 2025.